News - GlaxoSmithKline, Rituxan

Filter

Current filters:

GlaxoSmithKlineRituxan

Popular Filters

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Back to top